Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S127-33.

Angiogenesis inhibitors: a new class of drugs.

Author information

  • Harvard Medical School, Children's Hospital; Boston, Massachusetts 02115 USA. jadah.folkman@TCH.Harvard.edu

Abstract

Angiogenesis inhibitors belong to a new class of drugs. Many of these drugs are in clinical trials to treat cancer, while others have recently received FDA approval. However, angiogenesis inhibitors operate by different mechanisms than conventional cytotoxic chemotherapies, and require different guidelines for their optimum use in animal models and in humans. Some of the more significant guidelines of antiangiogenic therapy are assembled in this chapter, and their scientific basis is discussed.

PMID:
14508090
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Landes Bioscience
    Loading ...
    Write to the Help Desk